• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Aptose Biosciences Inc (OP:APTOF)

    1.712 +0.012 (+0.71%)
    Streaming Delayed Price Updated: 2:19 PM EDT, May 14, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Aptose Biosciences Inc

    News headline image
    Aptose Reports First Quarter 2026 Results
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders
    Aptose Biosciences and Hanmi Pharmaceutical to Further Extend Loan Agreement to Continue Development of Tuspetinib in Frontline Triplet Therapy for AML 
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical
    Aptose Biosciences minority shareholders to receive C$2.41 in cash per share in a “go private” transaction 
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Reports Third Quarter 2025 Results
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting
    Abstract available on ASH website 
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
    Data from Phase 1/2 TUSCANY trial presented at the European School of Haematology (ESH) 7th International Conference 
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor
    Aptose also Receives Additional Advance from Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML 
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Reports Second Quarter 2025 Results
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders
    Aptose to hold a reconvened shareholder meeting on August 22, 2025 at 10:00 a.m. (Eastern Time) to vote on appointment of new auditor 
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Upgraded to Trade on OTCQB Market
    Aptose will trade under the ticker symbol APTOF and begin trading on OTCQB today, July 1st 
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Announces Deferral of Interest Payment
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Provides Corporate Updates
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Announces Results from Annual and Special Meeting of Shareholders
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aptose Reports First Quarter 2025 Results
    Highlights Progress in TUSCANY Clinical Trial of Tuspetinib in AML Triple Frontline Therapy 
    From Aptose Biosciences, Inc.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.